| 李 新,孙万军,靳凤艳.20例存活7年以上多发性骨髓瘤患者临床观察[J].肿瘤学杂志,2014,20(7):574-577. |
| 20例存活7年以上多发性骨髓瘤患者临床观察 |
| Clinical Analysis of 20 Cases with Multiple Myeloma Surviving More Than 7 Years |
| 投稿时间：2014-03-21 |
| DOI：10.11735/j.issn.1671-170X.2014.07.B010 |
|
 |
| 中文关键词: 多发性骨髓瘤 生存期 预后 |
| 英文关键词:multiple myeloma survival prognosis |
| 基金项目: |
|
| 摘要点击次数: 2621 |
| 全文下载次数: 756 |
| 中文摘要: |
| 摘 要：［目的］ 分析生存期大于7年的多发性骨髓瘤患者的临床特点。［方法］ 回顾性分析了20例存活7年以上的多发性骨髓瘤患者的一般情况、临床特征、治疗与预后。［结果］ 7年存活率11.1%（20/180），10例（50.0%）患者在疾病进展期出现髓外瘤细胞的浸润。20例患者共接受了中位数28（15~41）个周期的化疗，复发患者接受了以硼替佐米为主的化疗方案、DECP方案、来那度胺、三氧化二砷及脂质体阿霉素治疗。20例患者的中位生存期为91（84~120）个月，至随访结束，仍有11例患者存活。［结论］多发性骨髓瘤的预后除与肿瘤负荷、宿主因素、肿瘤生物学等有关外，还与治疗措施及治疗反应密切相关。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the clinical characteristics of multiple myeloma(MM) patients surviving more than 7 years. ［Methods］ General condition，clinical features，treatment and prognosis of 20 cases with MM surviving more than 7 years were analyzed retrospectively.［Results］ The 7-year survival rate was 11.1%（20/180）. There were 10（50.0%）patients occurred extramedullary plasmacytomas during the progression of the diseases. The 20 patients had received the median of 28（15～41）cycles of chemotherapy. The relapsed MM patients had received chemotherapy based with bortezomib，DECP regimen，lenalidomide，Arsenic trioxide and pegylated liposomal doxorubicin. The median survival was 91（84～120）months. There were 11 patients still alive at the end of follow-up. ［Conclusion］ Besides tumor burden，host factors and tumor biology，the prognosis of MM correlates with the treatment modality and response to therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|